AI Leadership Expectations for the Pharma C-Suite in 2026

Why the Bar Has Changed

The expectations on pharma C-suite engagement with AI have shifted materially over the past 18-24 months. Three forces have driven the shift, and understanding them helps leaders calibrate their own engagement.

The first is regulator engagement. FDA, EMA, and PMDA have all moved AI from a research-coordinated topic to a senior-leadership topic in their formal interactions with pharma organizations. Inspections increasingly include questions about senior leadership’s role in AI governance. Submissions involving AI-derived evidence draw senior-level questions from agency reviewers. The signal is clear: AI is not a delegated technical matter — it’s a senior leadership accountability that the agencies expect to see exercised personally.

The second is board pressure. Pharma boards, like boards across industries, have moved from asking “what’s our AI strategy” to asking specific, sustained questions about portfolio decisions, capital allocation, risk posture, and operational performance. Boards that two years ago accepted glossy AI vision presentations now expect quarterly substance — investment performance against case, risk indicators trending, governance maturity advancing. The board has become a sustained governance customer, and the C-suite has to be able to engage at the level the board is now operating at.

The third is competitive separation. The gap between pharma organizations leading on AI and those trailing has widened to the point that it’s beginning to surface in operational performance, talent acquisition, and investor narrative. Organizations whose C-suites engage substantively are accelerating; organizations whose C-suites engage performatively are visibly falling behind. The gap is becoming hard to obscure.

What the CEO Has to Do Personally

The CEO’s accountability for AI cannot be delegated. The specific things the CEO has to do personally — meaning, things the CEO has to be visibly doing, not just things the CEO has to be ultimately accountable for — have crystallized.

Own the strategic narrative. The CEO has to be able to articulate, in their own voice and with their own judgment, what AI means for this specific company’s competitive trajectory. Not “we’re investing in AI like everyone else” — a real, defensible position about where AI creates durable advantage for this organization, what posture the company is taking, and why that posture is right for this company’s situation. Boards, investors, and the organization itself notice when the CEO is reciting the AI strategy versus owning it.

Sponsor the cross-functional governance. AI cuts across functions in ways most other strategic topics don’t. The CEO has to actively sponsor the cross-functional governance — through public investment of personal time, through resolving the cross-functional tensions that surface, and through holding peers accountable for engagement. Governance that doesn’t have CEO sponsorship visible in the room consistently underperforms governance that does.

Engage with talent personally. The talent that builds and runs AI capability is recruited, retained, and motivated significantly by the CEO’s personal engagement. Senior AI leaders read whether the CEO is genuinely interested in their work — and they have options. CEOs who engage substantively with their AI leadership build loyalty and continuity that compound; CEOs who don’t lose people to organizations that do.

Manage the public narrative. Pharma CEOs who speak publicly about AI — at industry events, in earnings calls, in investor meetings — set the standard their organizations work to meet. A CEO who speaks substantively about AI signals to the entire organization, and to talent considering joining, that this is a real strategic priority. A CEO who speaks generically signals the opposite.

Stay calibrated on pace. The CEO has to stay personally calibrated on the pace of change in the AI landscape — not in technical depth, but in directional awareness. Reading, engaging with peers, occasional time with senior practitioners. The CEO who falls behind on pace stops being able to make strategic decisions at the speed the landscape requires.

CFO: Capital Allocation and Financial Discipline

The CFO’s role on AI has expanded from “ensure the books are balanced” to “shape the capital allocation and impose the financial discipline that AI investments routinely lack.” The expansion has happened faster than many CFOs have positioned themselves for.

Five CFO accountabilities matter most:

• Capital allocation framework. The CFO has to ensure AI investments are evaluated against the same capital allocation rigor as other major capital requests — multi-year economics, sensitivity analysis, scenario planning, course correction triggers. AI strategies that come to the board without this rigor fail at higher rates than those that have it, and the CFO is the natural enforcer.
• Portfolio measurement. The portfolio of AI investments needs financial measurement against the cases made at approval. Most pharma organizations have weak measurement. The CFO has to build it — both because the board will ask, and because without it the portfolio drifts.
• Vendor and partnership financial diligence. AI vendor and partnership economics are frequently structured in ways that produce financial surprises. The CFO has to ensure procurement and partnership functions are surfacing the structural risks before signing, not after.
• Talent and capability investment economics. Building AI capability is expensive, talent-intensive, and slow to show financial returns. The CFO has to defend the long-cycle investment when budget pressure mounts — which requires having the framework that defends it.
• Risk and contingency reserves. AI deployments carry risks that other capital projects don’t — model failure, regulatory disruption, reputation. The CFO has to ensure appropriate contingency is reserved and that the organization has financial flexibility to respond when something happens.

The CFOs who position well on AI are the ones who treat it as a major capital allocation domain — not a side topic delegated to IT or strategy. That positioning requires building or hiring the financial analytical capability to engage substantively with AI economics, which most pharma CFOs have done less of than the situation now requires.

COO and R&D Heads: Operating Model and Pipeline Impact

The COO and R&D leaders bear the primary accountability for translating AI capability into operational and pipeline outcomes. The bar on each has risen considerably.

For the COO, the central accountability is operating model. AI changes how work gets done — clinical operations, manufacturing, supply chain, commercial operations, customer engagement. The operating model has to evolve in step. COOs who treat AI as a parallel track that doesn’t affect the core operating model produce AI investments that don’t translate into operational outcomes. COOs who actively design the operating model evolution capture the value the AI investments were made to enable.

Three operating model questions the COO has to answer personally:

• Where does AI change decision rights, hand-offs, or accountability — and how is the organization redesigning around the change?
• What’s the operating model for the AI capability itself — who owns it day-to-day, how is it staffed, how does it interact with the functions it serves?
• How does the operating model evolve as AI capability matures, and who’s responsible for ensuring the evolution actually happens rather than being deferred?

For the R&D head, the accountability is pipeline impact. AI investment in R&D has to translate into measurable pipeline outcomes — better targets, better trial design, faster development, higher success rates, lower cost per asset. The R&D head has to be able to articulate how AI is changing the pipeline trajectory and to defend the AI investment against alternatives at the level the board engages.

The R&D heads who position well on AI are the ones who have moved beyond “we’re investing in AI across discovery and development” to specific, measurable claims about pipeline impact — accompanied by infrastructure for measuring the claims and willingness to retire investments that aren’t producing.

Commercial Leadership: Customer-Facing AI

The commercial head’s accountability on AI has shifted from “use AI to be more efficient internally” to “navigate AI in customer-facing operations with the risk awareness the customer base requires.” The customer base — HCPs, patients, payers — is itself becoming more AI-aware, and commercial AI strategy has to reflect the more sophisticated customer.

Three commercial AI questions matter most:

• Customer-facing AI deployment. Where does the company deploy AI in interactions with HCPs, patients, or payers? What are the disclosure expectations, the regulatory obligations, the brand risk dimensions? Many commercial AI deployments today proceed without clear answers, accumulating risk that surfaces unpredictably.
• Information ecosystem navigation. AI is reshaping how HCPs and patients access pharmaceutical information — through AI-powered search, summarization tools, and increasingly conversational interfaces. The commercial head has to develop strategy for how the company’s products and information are represented in the AI-mediated information ecosystem.
• Sales force enablement and limits. AI tools for sales force productivity are widespread and deepening. The commercial head has to navigate the productivity case alongside the regulatory boundaries, brand voice consistency, and the practical question of which AI capabilities actually help the sales force versus which become friction.

Commercial heads who position well on AI are the ones who treat it as a strategic domain with its own governance, not as a feature set in CRM and marketing tools. The governance has to be commercially native — owned in commercial, integrated with commercial planning — rather than imposed from IT or quality.

Quality, Regulatory, and Legal Leadership

The quality, regulatory, and legal triad bears the most demanding governance accountability on AI in pharma. The expectations on each have risen sharply, and the talent and capability investments to meet them have not consistently kept pace.

The quality head has to ensure the AI governance framework actually works as a governance framework — tier classification, validation, change control, performance monitoring, inspection-readiness. The framework has to evolve as deployment scales. The quality head’s positioning depends on whether the framework is shaping decisions or being checked off after decisions are made.

The regulatory head has to lead substantive regulator engagement on AI — pre-submission meetings, scientific advice, workshop participation, response posture during inspection. The regulatory community is engaging seriously with pharma on AI, and the organizations that engage proactively get materially better outcomes than those that engage reactively.

The legal and privacy head has to navigate AI in contractual, IP, data privacy, and litigation dimensions that didn’t exist a few years ago. AI vendor contracting requires expertise that generic SaaS contracting templates don’t cover. AI IP issues — output ownership, training data exposure, derivative works — require specialized analysis. AI data privacy issues — across jurisdictions with diverging regulations — require sustained attention.

The triad’s joint operating model matters as much as each individual role. AI governance that doesn’t have quality, regulatory, and legal working in concert produces gaps that surface under inspection or litigation. The C-suite has to ensure the joint operating model is functioning, not just that each role is staffed.

The Common Gaps

Across the C-suite roles, several fluency and engagement gaps recur frequently. Naming them helps leaders recognize them in themselves and in peers.

Performative engagement without depth. The leader speaks publicly about AI, attends the steering committee, and signs off on investments — but doesn’t engage substantively with the decisions. Subordinates pick up the signal and adjust. The performative pattern is most common in CEOs but appears across the C-suite.

Delegating to a single function. The leader treats AI as someone else’s accountability — IT, data science, the chief AI officer if there is one. The cross-functional accountability that AI actually requires never materializes, and the program underperforms.

Outdated mental models. The leader’s mental model of AI is two or three years out of date. The pace of change has been fast enough that mental models from 2023-2024 are no longer adequate for 2026 decisions. Refreshing the mental model takes deliberate effort that many leaders haven’t invested.

Risk asymmetry. The leader engages enthusiastically with the upside of AI and minimally with the risk. The risk surface in pharma AI is real — regulatory, vendor, talent, model, reputation — and balanced engagement requires equivalent attention to both sides.

Talent under-investment. The leader doesn’t visibly invest in the AI talent under their function. Senior practitioners notice. Talent retention degrades. The capability erodes from below.

Building C-Suite AI Fluency

Closing the fluency gap requires deliberate, sustained investment. Several practices that work:

• Structured exposure to senior practitioners. Regular substantive time with the senior AI leadership inside and outside the company — not status meetings, real engagement with the work.
• Targeted reading and curation. A small number of high-quality sources read consistently builds calibration faster than scattered consumption. Most C-suite leaders need someone curating the curation rather than navigating the firehose themselves.
• Peer engagement. Conversations with C-suite peers at other pharma organizations, at industry forums, and through advisor relationships build pattern recognition that internal exposure alone doesn’t produce.
• Hands-on engagement with AI tools. The C-suite leaders who use AI tools personally build mental models that reading alone doesn’t produce. The investment is small; the return on judgment quality is meaningful.
• Coaching or advisory relationships. Several C-suite leaders are now working with external advisors who help them navigate AI decisions, refresh mental models, and stress-test positions. The investment is modest relative to the decisions it informs.

The C-suite that invests in collective fluency moves faster, decides better, and accumulates compounding advantage. The C-suite that doesn’t continues to make AI decisions at the level its current fluency supports — and watches the gap with leading peers widen quarter by quarter. The investment is small relative to the consequence; the consequence is increasingly visible.

The collective dimension

Individual C-suite fluency matters, but the collective fluency of the C-suite as a working group matters more. AI decisions in pharma routinely cut across CEO, CFO, COO, R&D, Commercial, Quality, Regulatory, and Legal — and the quality of cross-functional decision-making depends on the collective ability to engage substantively, surface concerns honestly, and converge on positions that hold under execution. C-suites where one or two members are deeply fluent and the rest are not produce uneven decisions and predictable cross-functional friction.

The corrective is to invest in C-suite fluency as a group activity, not just as individual professional development. Shared briefings, joint sessions with senior practitioners, and structured discussions of specific decisions in front of the group build collective calibration that individual development alone doesn’t produce. Several pharma C-suites have begun running quarterly half-day AI working sessions among themselves — not status reviews of programs, working sessions on the strategic and operational questions the group is navigating together. The reports back from organizations that have done this consistently are favorable: the collective fluency builds faster, the cross-functional decisions converge more cleanly, and the C-suite operates as a more coherent governance unit on AI than it did before.

References